title: Mast cell mediators and peritoneal adhesion formation in the rat.
abstract: We have previously shown that mast cell stabilization attenuates peritoneal adhesion formation in the rat. The present study investigated the mechanism of this protection. Adhesions were created in weanling rats using cecal scraping and application of 95% ethanol. Rats received specific blockers for the mast cell products histamine, serotonin (5HT), leukotriene D4, and platelet activating factor intraperitoneally 30 min before laparotomy and at the time of abdominal closure. Control animals received saline. Adhesions were assessed blindly 1 week later using a standardized scale. Adhesion formation was not affected by histamine blockade using combined mepyramine and ranitidine, 5-HT1 blockade using methysergide, 5-HT3 blockade using ondansetron, leukotriene D4 blockade using MK-571, or platelet activating factor blockade using WEB-2086. However, blockade of the 5-HT2 receptor using ketanserin resulted in significant dose-dependent attenuation of adhesions compared to saline. These data suggest that mast cells mediate peritoneal adhesion formation in the rat through release of serotonin acting on 5HT2 receptors. Further understanding of this process may lead to new strategies for the prevention of postoperative adhesions.
authors.affiliation: Intestinal Disease Research Unit, McMaster University, Hamilton, Ontario, Canada.
authors.forename: J C
authors.initials: JC
authors.lastname: Langer
authors.forename: S M
authors.initials: SM
authors.lastname: Liebman
authors.forename: P K
authors.initials: PK
authors.lastname: Monk
authors.forename: G J
authors.initials: GJ
authors.lastname: Pelletier
mesh_terms: D000818:Animals; D001381:Azepines; D004195:Disease Models, Animal; D006633:Histamine Antagonists / Q000494:pharmacology; D017998:Leukotriene D4 / Q000037:antagonists & inhibitors; D008297:Male; D008407:Mast Cells / Q000502:physiology*; D008784:Methysergide / Q000494:pharmacology; D017294:Ondansetron / Q000494:pharmacology; D010532:Peritoneal Diseases / Q000209:etiology* / Q000517:prevention & control; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D011422:Propionates / Q000494:pharmacology; D011738:Pyrilamine / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D011899:Ranitidine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D000267:Tissue Adhesions / Q000209:etiology / Q000517:prevention & control; D014230:Triazoles
chemical_list: D001381:Azepines; D006633:Histamine Antagonists; D010972:Platelet Activating Factor; D011422:Propionates; D011804:Quinolines; D012702:Serotonin Antagonists; D014230:Triazoles; C052518:WEB 2086; D017294:Ondansetron; C059141:verlukast; D017998:Leukotriene D4; D011899:Ranitidine; D011738:Pyrilamine; D008784:Methysergide